Small molecules for bone diseases

Expert Opinion on Therapeutic Patents

Volumn 20, Issue 4, 2010, Pages 563-582

  Masuya, Keiichi ^a   Teno, Naoki ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b HIROSHIMA INTERNATIONAL UNIVERSITY   (Japan)

Author keywords

v 3 antagonists; Bisphosphonate; Bone disease; Cathepsin K; Cyclooxygenase 2; MMP; Prostaglandin EP4 receptor; Secreted Frizzled related protein; Vacuolar H ATPase

Indexed keywords

7 [3 HYDROXY 2 [3 HYDROXY 4 (3 METHOXYMETHYLPHENYL) 1 BUTENYL] 5 OXOCYCLOPENTYL] 5 THIAHEPTANOIC ACID METHYL ESTER; ADENOSINE TRIPHOSPHATASE INHIBITOR; ALENDRONIC ACID; ALPHA5BETA3 INTEGRIN ANTAGONIST; AZETIDINE DERIVATIVE; BALICATIB; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CATHEPSIN K INHIBITOR; CYANIDE; ETIDRONIC ACID; FRI 77995; IBANDRONIC ACID; MACROLIDE; MATRIX METALLOPROTEINASE INHIBITOR; MINODRONIC ACID; MK 1256; MV 061194; ODANACATIB; PAMIDRONIC ACID; PARATHYROID HORMONE; PROSTAGLANDIN EP4 RECEPTOR AGONIST; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; PROTEIN INHIBITOR; PYRIDAZINE DERIVATIVE; PYRROLIDINE DERIVATIVE; RELACATIB; RISEDRONIC ACID; SB 223245; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOLEDRONIC ACID;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; BONE DENSITY; BONE DISEASE; BONE REMODELING; CANCER INHIBITION; CLINICAL TRIAL; DRUG BINDING; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; HUMAN; LUMBAR SPINE; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PATENT; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RHEUMATOID ARTHRITIS; TUMOR INDUCED OSTEOLYSIS; UNSPECIFIED SIDE EFFECT; VERTEBRA FRACTURE;

ANIMALS; BONE DISEASES; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG DISCOVERY; HUMANS; PATENTS AS TOPIC; QUALITY OF LIFE;

EID: 77949876498     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543771003604729     Document Type: Review

References (223)

1. Teitelbaum SL. Osteoclasts: what do they do and how they do it? Am J Pathol 2007;170:427-435
2. Fuller K, Kirstein B, Chambers TJ. Regulation and enzymatic basis of bone resorption by human osteoclasts. Clin Sci (Lond) 2007;112:567-575
3. Troen BR. Molecular mechanisms underlying osteoclast formation and activation. Exp Gerontol 2003;38:605-614
4. Asagiri M, Takayanagi H. The molecular understanding of osteoclast differentiation. Bone 2007;40:251-264
5. Blair HC, Robinson LJ, Zaidi M. Osteoclast signaling pathways. Biochem Biophys Res Commun 2005;328:728-738
6. Shinohara M, Takayanagi H. Novel osteoclast signaling mechanisms. Curr Osteoporos Rep 2007;5:67-72
7. Ducy P, Schinke T, Karsenty G. The osteoblast: a sophisticated fibroblast under central surveillance. Science 2000;289:1501-1504
8. Phan TC, Xu J, Zheng MH. Interaction between osteoblast and osteoclast: impact on bone disease. Histol Histopathol 2004;19:1325-1344
9. Sabokbar A, Athanasou NS. Generating human osteoclasts from peripheral blood. Methods Mol Med 2003;80:101-111
10. Sun S. Bone disease drug discovery: examing the interactions between osteoblast and osteoclast. Expert Opin Ther Targets 2008;12(2):239-251
11. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:1799-1809
12. Neer RM, Arnaud CD, Zanchetta RJ, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-1441
13. Chen P, Miller PD, Recker R, et al. Increases in bone mineral density correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis. J Bone Miner Res 2007;22:1173-1180
14. Uzzan B, Cohen R, Nicolas P, et al. Effects of statins on bone mineral density: a meta-analysis of clinical studies. Bone 2007;40:1581-1587
15. Von Baeyer H, Hofmann KS. Acetodiphosphoriga sauer. Ber 1897;30:1973
16. Francis MD, Valent DJ. Historical perspectives on the clinical development of bisphosphonates in the treatment of bone diseases. J Musculoskelet Neuronal Interact 2007;7(1):2-8
17. Fleisch H. Development of bisphosphonates. Breast Cancer Res 2002;4(1):30-34
18. Van Beek ER, Cohen LH, Leroy IM, et al. Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone 2003;33(5):805-811
19. Mukherjee S, Huang C, Oldfield E, et al. Thermodynamics of bisphosphonates binding to human bone: a two-site model. J Am Chem Soc 2009;131:8374-8375
20. Ebetino HF, Sietsema KW. Bisphosphonates in development for metabolic bone disease. Expert Opin Invest Drugs 1994;3(12):1255-1276
21. Benckiser AG. 1-Hydroxy-3-aminopropan- 1,1-diphosphonsaeure und Verfahren zu deren Herstellung. DE2130794; 1973
22. Henkel . . Verwendung von 3-Amino- 1-Hydroxypropan-1,1-diphosphonsaeure oder ihrer wasserloeslichen Salze bei der Beeinflussung von Calciumstoffwechselstoerungen im menschlichen oder tierischen Koerper. DE2405254; 1975
23. Instituto Gentili. Pharmaceutical composition based on diphosphonates for the treatment of arthrosis. EP203649; 1986
24. Procter&Gamble Co. Pharmaceutical compositions containing geminal diphosphonates. EP186405; 1986
25. Boehringer Mannheim. Disphosphonium acid derivatives and midicines containing the same. WO8800590; 1988
26. Novartis AG. Substituted alkanediphosphonic acids and pharmaceutical use. US4939130; 1990
27. Benhamou CL. Effects of osteoporosis medications on bone quality. Joint Bone Spine 2007;74:39-47
28. Close P, Neuprez A, Reginster JY. Developments in the pharmacotherapeutic management of osteoporosis. Expert Opin Pharmacother 2006;7:1603-1615
29. Heckbert SR, Li G, Cummings SR, et al. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 2008;168(8):826-831
30. Takeuchi M, Sakamoto S, Kawamuki K, et al. Studies on novel bone resorption inhibitors. II. Synthesis and pharmacological activities of fused aza-heteroarylbisphosphonate derivatives. Chem Pharm Bull 1998;46(11):1703-1709
31. Hagino H, Nishizaki Y, Sone T, et al. A bouble-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis. Bone 2009;44(6):1078-1084
32. Matsumoto T, Hagino H, Shiraki M, et al. Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study. Osteoporos Int 2009;20(8):1429-1437
33. Martin MB, Grimley JS, Oldfield E, et al. Bisphosphonates inhibit the growth of trypanosoma brucei, trypanosoma cruzi, leishmania donovani, toxoplasma gondii and plasmodium falciparum: a potential route to chemotherapy. J Med Chem 2001;44:909-916
34. Singh US, Shankar R, Hajela K, et al. Synthesis and biological evaluation of indolyl bisphosphonates as anti-bone resorptive and anti-leishmanial agents. Bioorg Med Chem 2008;16:8482-8491
35. The Board of Trustees of the University of Illinois. Bisphosphonate compounds and methods. WO07109585; 2007
36. Brown HK, Holen I. Anti-tumour effects of bisphosphonates - what have we learned from in vivo models? Curr Cancer Drug Targets 2009;9:807-823
37. Brounais B, Ruiz VC, Redini F, et al. Novel anti-cancer strategy in bone tumors by targeting molecular and cellular modulators of bone resorption. Recent Pat Anti Cancer Drug Discov 2008;3:178-186
38. Anderson P, Kopp L, Anderson N, et al. Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing' sarcoma and osteosarcoma). Expert Opin Investig Drugs 2008;17(11):1703-1715
39. Xie Y, Ding H, Qian L, et al. Synthesis and biological evaluation of novel bisphosphonates with dual activities on bone in vitro. Bioorg Med Chem Lett 2005;15:3267-3270
40. Sanders JM, Gomez AO, Oldfield E, et al. 3D QSAR investigations of the inhibition of leishmania major farnesyl pyrophosphate synthase by bisphosphonates. J Med Chem 2003;46:5171-5183
41. Inaoka T, Bilbe G, Ishibashi O, et al. Molecular cloning of human cDNA for cathepsin K: novel cysteine proteinase predominantly expressed in bone. Biochem Biophys Res Commun 1995;206(1):89-96
42. Garnero P, Borel O, Byrjalsen I, et al. The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem 1998;273:32347-32352
43. Saftig P, Hunziker E, Wehmeyer O, et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci USA 1998;95:13453-13458
44. Cai J, Jamieson C, Moir J, Rankovic Z. Cathepsin K inhibitors, 2000-2004. Expert Opin Ther Pat 2005;15(1):33-48
45. Matsumoto K, Mizoue K, Kitamura K, et al. Structural basis of inhibition of cysteine proteases by E-64 and its derivatives. Biopolymers 1999;51(1):99-107
46. Yamashita DS, Dodds RA. Cathepsin K and the design of inhibitiors of cathepsin K. Curr Pharm Des 2000;6(1):1-24
47. Shaw E, Green GD. Inactivation of thiol proteases with peptidyl diazomethyl ketones. J Methods Enzymol 1981;80(Pt C):820-826
48. Shaw E. The selective inactivation of thiol proteases in vitro and in vivo. J Protein Chem 1984;3:109-120
49. Powers JC, Asgian JL, James KE, et al. Irreversible inhibitors of serine, cysteine, and threonine proteases. Chem Rev 2002;102:4639-4750
50. Leung-Toung R, Li W, Tam TF, et al. Thiol-dependent enzymes and their inhibitors: a review. Curr Med Chem 2002;9:979-1002
51. Rasnick D. Small synthetic inhibitors of cysteine proteases. Perspect Drug Discov Des 1996;6:47-63
52. McKerrow JH, Engel JC, Caffrey CR. Cysteine protease inhibitors as chemotherapy for parasitic infections. Bioorg Med Chem 1999;7:639-644
53. Hanzlik RP, Thompson SA. Vinylogous amino acid esters: a new class of inactivators for thiol proteases. J Med Chem 1984;27:711-712
54. Thompson SA, Andrews PR, Hanzlik RP. Carbonyl-modified amino acids and peptides as protease inhibitors. J Med Chem 1986;29:104-111
55. Kong J-S, Venkatraman S, Furness K, et al. Synthesis and evaluation of peptidyl michael acceptors that inactivate human rhinovirus 3C protease and inhibit virus replication. J Med Chem 1998;41:2579-2587
56. Dragovich PS, Webber SE, Babine RE, et al. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. michael acceptor structure-activity studies. J Med Chem 1998;41:2806-2818
57. Smithkline Beecham Corp. Novel cathepsin K inhibitors. WO05013909; 2005
58. Yamashita DS, Marquis RW, Xie R, et al. Structure activity relationships of 5-, 6-, and 7-methyl-substituted azepan-3-one cathepsin K inhibitors. J Med Chem 2006;49:1597-1612
59. Wang H, Matsuhashi H, Doan DB, et al. Large-scale synthesis of SB-462795, a cathepsin K inhibitor: the RCM-based approaches. Tetrahedron 2009;65:6291-6303
60. Medivir AB. Furanone derivatives as cysteine protease inhibitors. EP1916248; 2008
61. Medivir AB. Cysteine protease inhibitors. WO09000877; 2009
62. Amura Therapeutics Ltd. Biologically active compounds. WO04007501; 2004
63. Amura Therapeutics Ltd. Compounds. WO09087379; 2009
64. Novartis AG. Dipeptide nitrile cathepsin K inhibitors. WO01058886; 2001
65. Novartis AG. Use of cathepsin K inhibitors in severe bone loss diseases. WO05049028; 2005
66. Altmann E, Aichholz R, Betchart C, et al. Dipeptide nitrile inhibitors of cathepsin K. Bioorg Med Chem Lett 2006;16:2549-2554
67. Adami S, et al. Effect of one year treatment with the cathepsin-K inhibitor, balicatib, on bone mineral density (BMD) in postmenopausal woman with osteopenia/osteoporosis. American Society for Bone and Mineral Research, Washington, DC; 17 September 2006
68. Gauthier JY, Chauret N, Cromlish W, et al. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett 2008;18:923-928
69. Rodan SB, Duong LT. Cathepsin K - A new molecular target for osteoporosis. IBMS BoneKEy 2008;5:16-24
70. Stoch SA, Zajic S, Stone J, et al. Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase i studies. Clin Pharmacol Ther 2009;86(2):175-182
71. Merck Frosst Canada Ltd. Cathepsin cysteine protease inhibitors. WO07003056; 2007
72. Robichaud J, Black WC, Crane SN, et al. Identification of a nonbasic, nitrile-containing cathepsin K inhibitor (MK-1256) that is efficausious in a monkey model of osteoporosis. J Med Chem 2008;51:6410-6420
73. Merck Frosst Canada Ltd. Cathepsin cysteine protease inhibitors. WO08116302; 2008
74. F. Hoffmann-La Roche AG. Cathepsin K inhibitors. WO07014839; 2007
75. Astrazeneca AG. Cyanocyclopropylcarboxamides as cathepsin inhibitors. WO09001127; 2009
76. Astrazeneca AG. 1,2-Cyclohexane dicarboxamides as cathepsin inhibitors. WO09001128; 2009
77. Astrazeneca AG. 1-Cyanocyclopropylderivatives as cathepsin K inhibitors. WO09001129; 2009
78. Sanofi-Aventis. Spirocyclic nitriles as protease inhibitors. WO07137738; 2007
79. Novartis AG. Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin K inhibitory activity for the treatment of inflammations and other diseases. WO03020278; 2003
80. Novartis AG. Spiro-substituted pyrrolopyrimidines. WO04076455; 2004
81. Teno N, Masuya K, Ehara T, et al. Effect of cathepsin K inhibitors on bone resorption. J Med Chem 2008;51:5459-5462
82. Astrazeneca AG. Pteridine derivatives and their use as cathepsin inhibitors. WO07148064; 2007
83. Ono Pharmaceutical Co., Ltd. Nitriles and medicinal compositions containing the same as the active ingredient. WO05085210; 2005
84. Glaxo Group Ltd. 2,4-Substituted pyrimidines as cysteine protease inhibitors. WO06027211; 2006
85. Glaxo Group Ltd. Novel substituted pyrimidines as cysteine protease inhibitors. WO08052934; 2008
86. N.V Organon. 2-Cyano-1,3,5-triazine- 4,6-diamine derivatives. WO05011703; 2005
87. N.V Organon. Preparation of 6-phenyl- 1H-imidazo[4,5-c]pyridine-4- carbonitrile derivatives as cathepsin inhibitors. WO09010491; 2009
88. Merck Frosst, Axys Pharma, Inc and Banyu Pharma Co, Ltd. Cathepsin cysteine protease inhibitors. WO01077073; 2001
89. Korea Research Institute of Chemical Technology. Preparation of hexahydropyridazine-carbonitriles and related compounds as cathepsin K inhibitors. KR0769467; 2007
90. Kim SH, Jhon DJ, Kang NS, et al. Effect of novel N-cyano- tetrahydropyridazine compounds, a class of cathepsin K inhibitors, on the bone resorptive activity of mature osteoclasts. Bioorg Med Chem Lett 2008;18:3988-3991
91. Duong LT, Rodan GA. Integrinmediated signaling in the regulation of osteoclast adhesion and activation. Front Biosci 1998;3:d757-68
92. Aumailley M, Gurrath M, Muller G, et al. Arg-Gly-Asp constrained within cyclic pentapoptides Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett 1991;291:50-54
93. Bach AC, Espina JR, et al. Type II to type I beta-turn swap changes specificity for integrins. J Am Chem Soc 1996;118:293-294
94. Burgess K, Lim D, Mousa SA. Synthesis and solution conformation of cyclo [RGDRGD]: a cyclic peptide with selectivity for the alphavbeta3 receptor. J Med Chem 1996;39:4520-4526
95. Gatto AD, Zaccaro L, Grieco P, et al. Novel and selective alphavbeta3 receptor peptide antagonist: design, synthesis, and biological behavior. J Med Chem 2006;49:3416-3420
96. Zanardi F, Burreddu P, Rassu G, et al. Discovery of subnanomolar arginineglycine- aspartate-based alphaVbeta3/ alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem 2008;51:1771-1782
97. Indrevoll B, Kindberg GM, Solbakken M, et al. NC-100717: a versatile RGD peptide scaffold for angiogenesis imaging. Bioorg Med Chem Lett 2006;16:6190-6193
98. Banfi L, Basso A, Damonte G, et al. Synthesis and biological evaluation of new conformationally biased integrin ligands based on tetrahydroazoninone scaffold. Bioorg Med Chem Lett 2007;17:1341-1345
99. Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Cyclopeptide derivatives with anti-integrin activity. WO05111064; 2005
100. Universite' Degli Studi Milano. Peptidomimetic compounds and preparation of biologically active derivatives. WO06092722; 2006
101. Del Gatto A, Zaccaro L, Pedone C, et al. Selective alphavbeta3 receptor peptide antagonist for therapeutic and diagnostic application. WO07042241; 2007
102. Keenan RM, Milller WH, Kwon C, et al. Discovery of potent nonpeptide vitronectin receptor (alphavbeta3) antagonists. J Med Chem 1997;40:2289-2292
103. Kling A, Backfisch G, Delzer J, et al. Synthesis and SAR of N-substituted dibenzazepinone derivatives as novel potent and selective alphavbeta3 antagonists. Bioorg Med Chem Lett 2002;12:441-446
104. Corbett JW, Graciani NR, Mousa S, et al. Solid-phase synthesis of a selective alphavbeta3 integrin antagonist library. Bioorg Med Chem Lett 1997;7:1371-1376
105. Pitts WJ, Wityak J, Smallheer JM, et al. Isoxazolines as potent antagonists of the integrin alphavbeta3. J Med Chem 2000;43:27-40
106. Penning TD, Khilevich A, Chen BB, et al. Synthesis of pyrazoles and isoxazoles as potent alphavbeta3 receptor antagonists. Bioorg Med Chem Lett 2006;16:3156-3161
107. Batt DG, Petraitis JJ, Houghton GC, et al. Disubstituted indazoles as potent antagonists of the integrin alphavbeta3. J Med Chem 2000;43:41-58
108. Duggan ME, Duong LT, Fisher JE, et al. Nonpeptide alphavbeta3 antagonists. 1. Transformation of a potent, integrin-selective alphaIIbbeta3 antagonist into a potent alphavbeta3 antagonist. J Med Chem 2000;43:3736-3745
109. Gopalsamy A, Yang H, Ellingboe JW, et al. Parallel solid-phase synthesis of vitronectin receptor (alphavbeta3) inhibitors. Bioorg Med Chem Lett 2000;10:1715-1718
110. Meissner RS, Perkins JJ, Duong LT, et al. Nonpeptide alphavbeta3 antagonists. Part 2: constrained glycyl amides derived from the RGD tripeptide. Bioorg Med Chem Lett 2002;12:25-29
111. Perkins JJ, Duong LT, Fernandez- Metzler C, et al. Non-peptide alphavbeta3 Antagonists: identification of potent, chain-shortened RGD mimetics that incorporate a central pyrrolidinone constraint. Bioorg Med Chem Lett 2003;13:4285-4288
112. Hutchinson JH, Halczenko W, Brashear KM, et al. Nonpeptide alphavbeta3 Antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosis. J Med Chem 2003;46:4790-4798
113. Coleman PJ, Brashear KM, Askew BC, et al. Nonpeptide alphavbeta3 antagonists. part 11: discovery and preclinical evaluation of potent alphavbeta3 antagonists for the prevention and treatment of osteoporosis. J Med Chem 2004;47:4829-4837
114. Lange UEW, Backfisch G, Elzer J, et al. Synthesis of highly potent and selective hetaryl ureas as integrin alphavbeta3- Receptor antagonists. Bioorg Med Chem Lett 2002;12:1379-1382
115. Zechel C, Backfisch G, Delzer J, et al. T. Highly potent and selective alphaVbeta3-receptor antagonists: solid-phase synthesis and SAR of 1-substituted 4-amino-1H-pyrimidin- 2-ones. Bioorg Med Chem Lett 2003;13:165-169
116. Urbahns K, Harter M, Albers M, et al. Biphenyls as potent vitronectin receptor antagonists. Bioorg Med Chem Lett 2002;12:205-208
117. Urbahns K, Harter M, Albers M, et al. Biphenyls as potent vitronectin receptor antagonists. Part 3: squaric acid amides. Bioorg Med Chem Lett 2007;17:6151-6154
118. Seitz W, Geneste H, Backfisch G, et al. Design and synthesis of novel potent and selective integrin alphavbeta3 antagonists-Novel synthetic routes to isoquinolinone, benzoxazinone, and quinazolinone acetates. Bioorg Med Chem Lett 2008;18:527-531
119. Raboisson P, DesJarlais RL, Reed R, et al. Identification of novel short chain 4-substitute indoles as potent alphavbeta3 antagonists using structure based drug design. Eur J Med Chem 2007;42:334-343
120. The Government of the United State, As Represented by the Secretary of Health and Human service, National Institutes of Health. Integrin alphavbeta3 antagonists for use in imaging and therapy. WO06015382; 2006
121. Ube Industries, Ltd. Benzazepinone compound. WO09063990; 2009
122. Pharmacopeia Drug Discovery, Inc. Nitrogen heterocycle biaryls for osteoporosis and other diseases. WO07001249; 2007
123. Pharmacopeia, Inc. Nitrogen heterocycle biaryls for osteoporosis and other diseases. US05022q2203; 2005
124. Pharmacia Corporation. Biphenyl integrin antagonists. WO06043930; 2006
125. Zeng G-Z, Tan N-H, Hao X-J, et al. Natural inhibitors targeting osteoclast-mediated bone resorption. Bioorg Med Chem Lett 2006;16:6178-6180
126. Eliceiri BP, Cheresh DA. The role of Rv integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest 1999;103:1227-1230
127. Kumar CC. Integrin alphavbeta3 as a therapeutic target for blocking tumor induced angiogenesis. Curr Drug Targets 2003;4:123-131
128. Clezardin P. Recent insights into the role of integrins in cancer metastasis. Cell Mol Life Sci 1998;54:541-548
129. Letourneau JJ, Liu J, Ohlmeyer MHJ, et al. Synthesis and initial evaluation of novel, non-peptidic antagonists of the alphav-integrins alphavbeta3 and alphavbeta5. Bioorg Med Chem Lett 2009;19:352-355
130. Huxley-Jones J, Foord SM, Barnes MR. Drug discovery in the extracellular matrix. Drug Discovery Today 2008;13:685-694
131. Rowan AD, Litherland GJ, Hui M, et al. Metalloproteases as potential therapeutic targets in arthritis treatment. Expert Opin Ther Targets 2008;12:1-18
132. Hu J, Van den Steen PE, Sang Q-X A, Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 2007;6:480-498
133. Roach HI. Potential directions for drug development for osteoarthritis. Expert Opin Drug Discov 2008;3:475-486
134. MacPherson LJ, Bayburt EK, Capparelli MP, et al. Discovery of CGS27023A, a nonpeptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. J Med Chem 1997;40:2525-2532
135. Walker K. Activity of a selective inhibitor of collagenase-3 in models of arthritis. First Annual International Conference on Orthopaedic Biomaterials, San Diego, CA, December 11-12, 1997.
136. Campbell, J. A. Discovery of RS-130830, a potent and selective MMP inhibitor for osteoarthritis. Book of Abstracts, 216th ACS National Meeting; American Chemical Society. Washington, DC, 1998; MEDI-004
137. Chau T, Jolly G, Plym JM, et al. Inhibition of articular cartilage degradation in dog and guinea pig models of osteoarthritis by the stromelysin inhibitor BAY 12-9566. Arthritis Rheum 1998;41:S300
138. Lorenz H-M. Ro-32-3555 Roche Holding. Curr Opin Anti Inflamm Immunol Invest Drugs 2000;2:47-52
139. Rhomberg W. Marimastat (British Biotech plc.). Curr Opin Oncol Endocrinol Metab Invest Drugs 1999;1:507-524
140. Griffioen AW. AG-334. IDrugs 2000;3:336-345
141. Levin JI. The design and synthesis of aryl hydroxamic acid inhibitors of MMPs and TACE. Curr Top Med Chem 2004;4:1289-1310
142. Cherney RJ, Mo R, Meyer DT, et al. Sultam hydroxamates as novel matrix metalloproteinase inhibitors. J Med Chem 2004;47:2981-2983
143. Rossello A, Nuti E, Carelli P, et al. N-i-Propoxy- Nbiphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP. Bioorg Med Chem Lett 2005;15:1321-1326
144. Biasone A, Tortorella P, Campestre C, et al. alpha-Biphenylsulfonylamino 2-methylpropyl phosphonates: enantioselective synthesis and selective inhibition of MMPs. Bioorg Med Chem 2007;15:791-799
145. Moroy G, Denhez C, Mourabit HE, et al. Simultaneous presence of unsaturation and long alkyl chain at P'1 of Ilomastat confers selectivity for gelatinase A (MMP-2) over gelatinase B (MMP-9) inhibition as shown by molecular modelling studies. Bioorg Med Chem 2007;15:4753-4766
146. Gilbert AM, Bursavich MG, Lombardi S, et al. N-((8-Hydroxy-5- substitutedquinolin- 7-yl)-(phenyl)methyl)-2- phenyloxy/amino-acetamide inhibitors of ADAMTS-5 (Aggrecanase-2). Bioorg Med Chem Lett 2008;18:6454-6457
147. Wada CK. The evolution of the matrix metalloproteinase inhibitor drug discovery program at Abbott laboratories. Curr Top Med Chem 2004;4:1255-1267
148. Hanessiana S, Moitessier N. Sulfonamide-based acyclic and conformationally constrained MMP inhibitors: from computer-assisted design to nanomolar compounds. Curr Top Med Chem 2004;4:1269-1287
149. Sang Q-X A, Jin Y, Newcomer RG, et al. Matrix metalloproteinase inhibitors as prospective agents for the prevention and treatment of cardiovascular and neoplastic diseases. Curr Top Med Chem 2006;6:289-316
150. Vernalis (Oxford) Limited and Laboratories Serono S.A. Derivatives of hydroxamic acid as metalloproteinase inhibitors. WO05019194; 2005
151. Applied Research Systems Ars Holding N.V. N-Hydroxyamide derivatives and use thereof. WO07060132; 2007
152. Galapagos NV. Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases. WO08065199; 2008
153. Takaishi H, Kimura T, Delal S, et al. Joint diseases and matrix metalloproteinases: a role for MMP-13. Curr Pharm Biotechnol 2008;9:47-54
154. Monovich LG, Tommasi RA, Fujimoto RA, et al. Discovery of potent, selective, and orally active carboxylic acid based inhibitors of matrix metalloproteinase-13. J Med Chem 2009;52:3523-3538
155. Reiter LA, Freeman-Cook KD, Jones CS, et al. Potent, selective pyrimidinetrionebased inhibitors of MMP-13. Bioorg Med Chem Lett 2006;16:5822-5826
156. Li J, Rush TS III, Li W, et al. Synthesis and SAR of highly selective MMP-13 inhibitors. Bioorg Med Chem Lett 2005;15:4961-4966
157. Noe MC, Natarajan V, Snow SL, et al. Discovery of 3,3-dimethyl-5- hydroxypipecolic hydroxamate-based inhibitors of aggrecanase and MMP-13. Bioorg Med Chem Lett 2005;15:2808-2811
158. Skotnicki JS, DiGrandi MJ, Levin JI. Design strategies for the identification of MMP-13 and TACE inhibitors. Curr Opin Drug Discov Dev 2003;6:742-759
159. Novartis AG. Selective hydroxamate based MMP inhibitors. WO07117981; 2007
160. Warner-Lambert Company LLC. Thiazine and oxazine derivatives as MMP-13 inhibitors for treating arthritis. WO04000321; 2004
161. Warner-Lambert Company LLC. 5, 6-Fused 3, 4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors. WO04014869; 2004
162. Aventis Pharma Deutschland GMBH. Novel pyrimidine-4, 6-dicarboxamides for the selective inhibition of collagenases. WO04041788; 2004
163. Ishibashi O, Niwa S, Kadoyama K, et al. MMP-9 antisense oligodeoxynucleotide exerts an inhibitory effect on osteoclastic bone resorption by suppressing cell migration. Life Sci 2006;79:1657-1660
164. Liu X, Wu H, Byrne M, et al. A targeted mutation at the known collagenase cleavage site in mouse type I collagen impairs tissue remodelling. J Cell Biol 1995;130:227-237
165. Lind T, McKie N, Wendel M, et al. The hyalectan degrading ADAMTS-1 enzyme is expressed by osteoblasts and upregulated at regions of new bone formation. Bone 2005;36:408-417
166. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999;79:1193-1226
167. Takahashi S, Takeuchi K, Okabe S. EP4 receptor mediation of prostaglandin E2-stimulated mucus secretion by rabbit gastric epithelial cells. Biochem Pharmacol 1999;58:1997-2002
168. Graham S, Gamie Z, Polyzois I, et al. Prostaglandin EP2 and EP4 receptor agonists in bone formation and bone healing: In vivo and in vitro evidence. Expert Opin Investig Drugs 2009;18:749-766
169. Maruyama T, Asada M, Shiraishi T, et al. Design and synthesis of a selective EP-4 receptor agonists. Part 13: 16- Phenyl-5-thiaPGE1 and 9-beta-halo derivatives with improved stability. Bioorg Med Chem 2002;10:1743-1759
170. Yoshida K, Oida H, Kobayashi T, et al. Stimulation of bone formation and prevention of bone loss by prostaglandin E E4 receptor activation. Proc Natl Acad Sci USA 2000;99:4580-4585
171. Hagino H, Kuraoka M, Kameyama Y, et al. Effect of a selective agonist for prostaglandin E receptor subtype EP4 (ONO-4819) on the cortical bone response to mechanical loading. Bone 2005;36:444-453
172. Toyoda H, Terai H, Sasaoka R, et al. Augmentation of bone morphogenetic protein-induced bone mass by local delivery of a prostaglandin E EP4 receptor agonist. Bone 2005;37:555-562
173. Nakagawa K, Imai Y, Ohta Y, et al. Prostaglandin E2 EP4 agonist (ONO- 4819) accelerates BMP-induced osteoblastic differentiation. Bone 2007;41:543-548
174. Ono Pharmaceutical Co., Ltd. 5-Thia-wsubstituted phenyl-prostaglandin E derivatives, process for producing the same and drugs containing the same as the active ingredient. WO0003980; 2000
175. Elworthy TR, Brill ER, Chiou S-S, et al. Lactams as EP4 prostanoid receptor agonists. 3. Discovery of N-ethylbenzoic acid 2-pyrrolidines as subtype selective agents. J Med Chem 2004;47:6124-6127
176. Elworthy TR, Kertesz DJ, Kim W, et al. Lactams as EP4 prostanoid receptor subtype selective agonists. Part 1: 2- Pyrrolidinones-stereochemical and lower side-chain optimization. Bioorg Med Chem Lett 2004;14:1655-1659
177. Elworthy TR, Brill ER, Caires CC, et al. Lactams as prostanoid receptor ligands. Part 4: 2-Piperidones as selective EP4 receptor agonists. Bioorg Med Chem Lett 2005;15:2523-2526
178. Cameron KO, Lefker BA, Chu-Moyer MY, et al. Discovery of highly selective EP4 receptor agonists that stimulate new bone formation and restore bone mass in ovariectomized rats. Bioorg Med Chem Lett 2006;16:1799-1802
179. Xiao Y, Araldi GL, Zhao Z, et al. Discovery of novel prostaglandin analogs of PGE2 as potent and selective EP2 and EP4 receptor agonists. Bioorg Med Chem Lett 2007;17:4323-4327
180. Xiao Y, Araldi GL, Zhao Z, et al. Synthesis and evaluation of a gammalactam as a highly selective EP2 and EP4 receptor agonist. Bioorg Med Chem Lett 2008;18:821-824
181. Xiao Y, Araldi GL, et al. Synthesis and evaluation of a gamma-lactam as a highly selective EP2 and EP4 receptor agonist. Bioorg Med Chem Lett 2008;18:821-824
182. Merck Frosst Canada Ltd. Indoline amide derivatives as EP4 receptor ligands. WO07143825; 2007
183. Glaxo Group Ltd. Benzo [F] isoindoles as EP4 receptor agonists. WO08012347; 2008
184. Glaxo Group Ltd. Isoindol derivatives as EP4 receptor agonists. WO08046798; 2008
185. Glaxo Group Ltd. Benzoisoindole derivatives and their as EP4 receptor agonists. WO08061955; 2008
186. Janssen Pharmaceutica N.V. Benzamide derivatives as EP4 receptor agonists. WO08092860; 2008
187. Janssen Pharmaceutica N.V. Bicyclic derivatives as EP4 agonists. WO08092861; 2008
188. Janssen Pharmaceutica N.V. Bicyclic derivatives as EP4 agonists. WO08092862; 2008
189. Bowmann EJ, Siebers A, Altendorf K. Bafilomycine: a class of inhibitors of membrane ATPase from microorganism, animal cells, and plant cells. Proc Natl Acad Sci USA 1988;85:7972-7976
190. Drose S, Bindseil KU, Bowman EJ, et al. Inhibitory effect of modified bafilomycins and concanamycins on Pand V-type adenosinetriphosphatases. Biochemistry 1993;32:3902-3906
191. Sundquist K, Lakkakorpi P, Wallmark B, et al. Inhibition of osteoclast proton transport by bafilomycin A1 abolishes bone resorption. Biochem Biophys Res Commun 1990;168:309-313
192. Farina C, Gagliardi S. Selective inhibitors of vacuolar H+-ATPase of osteoclasts with bone antiresorptive activity. Exp Opin Ther Patents 1999;9:157-168
193. Mizunashi K, Furukawa Y, Katano K, et al. Effect of omeprazole, an inhibitor of H+, K+-ATPase, on bone resorption in humans. Calcif Tissue 1993;53:21-25
194. Beutler AJ, Mckee TC. Novel marine and microbial natural product inhibitors of vacuolar ATPase. Curr Med Chem 2003;10:787-796
195. Astrazeneca AB. Novel trisubstituted pyridine compounds. WO01025204; 2001
196. Astrazeneca AB. Novel nicotinonitrile compounds. WO01025207; 2001
197. Astrazeneca AB. Novel imidazopyridine carbonitrile compounds. WO01025237; 2001
198. Edvinsson KM, Herslof M, Holm P, et al. Solid phase synthesis of diamines as potential bone resorption inhibitors. Bioorg Med Chem Lett 2000;10:503-507
199. Fujisawa Pharma Co., Ltd. Benzimidazole derivatives and their use in the prevention and/or the treatment of bone dieseas. WO9 710219; 1997
200. Niikura K, Nakajima S, Takano M, et al. FR177995, a novel vacuolar ATPase inhibitor, exerts not only an inhibitory effect on bone destruction but also anti-immunoinflammatory effects in adjuvant-induced arthritic rats. Bone 2007;40:888-894
201. Holliday LS, Lu M, Lee BS, et al. The amino-terminal domain of the B subunit of vacuolar H+-ATPase contains a filamentous actin binding site. J Biol Chem 2000;275:32331-32337
202. Chen SH, Bubb MR, Yarmola EG, et al. Vacuolar H+-ATPase binding to microfilaments: regulation in response to phosphatidylinositol 3-kinase activity and detailed characterization of the actinbinding site in subunit B. J Biol Chem 2004;279:7988-7998
203. Ostrov DA, Magis AT, Wronski TJ, et al. Identification of enoxacin as an inhibitor of osteoclast formation and bone resorption by structure-based virtual screening. J Med Chem 2009;52:5144-5151
204. Pinson KI, Brennan J, Monkley S, et al. An LDL-receptor-related protein mediates Wnt signalling in mice. Nature 2000;407:535-538
205. Roman-Roman S, Shi D-L, Stiot V, et al. Murine frizzled-1 behaves as an antagonist of the canonical Wnt/bcatenin signaling. J Biol Chem 2004;279:5725-5733
206. Bodine PVN, Billiard J, Moran RA, et al. The Wnt antagonist secreted frizzledrelated protein-1 controls osteoblast and osteocyte apoptosis. J Cell Biochem 2005;96:1212-1230
207. Bodine PVN, Zhao W, Kharode YP, et al. The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice. Mol Endocrinol 2004;18:1222-1237
208. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-1441
209. Hoeppner LH, Secreto FJ, Westendorf JJ. Wnt signaling as a therapeutic target for bone diseases. Expert Opin Ther Targets 2009;13:485-496
210. Bodine PVN, Seestaller-Wehr L, Kharode YP, et al. Bone anabolic effects of parathyroid hormone are blunted by deletion of the Wnt antagonist secreted frizzled-related protein-1. J Cell Phys 2007;210:352-357
211. Gopalsamy A, Shi M, Stauffe B, et al. Identification of diarylsulfone
212. Moore WJ, Kern JC, Bhat R, et al. Modulation of Wnt signaling through inhibition of secreted Frizzled-Related Protein I (sFRP-1) with N-substituted piperidinyl diphenylsulfonyl sulfonamides. J Med Chem 2009;52:105-116
213. Wyeth. Preparation of diarylsulfone sulfonamides and their use as secreted frizzled related protein-1 modulators for bone disorders such as osteoporosis. US060276464; 2006
214. Wyeth. Piperidinyl arylsulfone derivatives as modulators of secreted frizzled-related protein-1. WO08060999; 2008
215. Wyeth. Iminothiazolidinone derivatives as sFRP-1 antagonists. WO06124887; 2006
216. Wyeth. Indole sulfonamides as sFRP-1 modulators. WO08060998; 2008
217. Wyeth. Substituted inden-2-yl, tetrahydronaphthalen-2yl, or dihydro-2H-chromen-3-yl arylsulfonamides and methods of their use. WO08061006; 2008
218. Mohamed MM, Sloane BF. Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 2006;6:764-775
219. Gall CL, Bellahcene A, Bonnelye E, et al. Cathepsin K inhibitor reduces breast cancer-induced osteolysis and skeletal tumor burden. Cancer Res 2007;67:9894-9902
220. Gibofsky A. Clinical profiles of celecoxib and rofecoxib in the rheumatic diseases. J Hypertens 2002;20:S25-30
221. Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999;282:1921-1928
222. Konstantin C, Loretta L, Paolo T, et al. NO-Donor COX-2 inhibitors. New nitrooxy-substituted 1,5-diarylimidazoles endowed with COX-2 inhibitory and vasodilator properties. J Med Chem 2007;50:1449-1457
223. Laboratories del Dr. Esteve SA. Preparartion of substituted azetidines as cyclooxygenase-1 and cyclooxygenase-2 inhibitors. US2007093469; 2007